The Korea Centers for Disease Control and Prevention has decided to withdraw its appeal filed against the COVID-19 vaccination damage compensation ruling and pay the plaintiff a subsidy.
However, it did not recognize the causality between the plaintiff's brain disease and vaccination, but chose to support it as an existing vaccine-related suspected disease.
(Picture from Unsplash)
The Korea Centers for Disease Control and Prevention said the damage compensation committee initially judged that side effects such as cerebral hemorrhage suffered by the plaintiff were more likely to be caused by other causes than vaccines, but admitted new facts that were not considered in the previous deliberation during further discussions.
The Korea Centers for Disease Control and Prevention explained that it decided to apply after conducting a detailed opinion inquiry, concluding that the plaintiff's symptoms could be supported as "Guillain-Barre syndrome," a suspected vaccine-related disease, not a brain disease.
After receiving the AstraZeneca vaccine in April last year, A, a man in his 30s, was diagnosed with intracerebral hemorrhage, cerebral spongiform encephalopathy, and applied for 3.37 million won in medical expenses and 250,000 won in nursing expenses, but the Korea Centers for Disease Control and Prevention rejected it after deliberation.
A filed an administrative lawsuit, and the Seoul Administrative Court ruled in favor of the plaintiff, saying, "It is reasonable to see that there is a causal relationship between disease and vaccination."
Writer: Yeyoung Jeon
Comments